FibroGen, Inc. Securities Litigation Settlement
This settlement is closed to new claims. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.
Do you qualify?
Anyone who purchased or acquired FibroGen, Inc. securities, including options, between December 20, 2018 and July 15, 2021, inclusive. Excluded are defendants, company officers and directors during the class period, their immediate family members, and entities they owned or controlled.
How to file
Contact the Claims Administrator at (877) 595-0137 or Info@FibroGenSecuritiesLitigation.com. The settlement is in distribution phase as of February 12, 2025, with ongoing rolling distributions to approved claimants. No new claims appear to be accepted as the distribution has already commenced.
Common questions
- How much does the FibroGen, Inc. Securities Litigation Settlement pay?
- The total settlement fund is $28.5M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- Is the FibroGen, Inc. Securities Litigation Settlement notice real, or a scam?
- JND Legal Administration is the settlement administrator for this case. Claims are filed at fibrogensecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the FibroGen, Inc. Securities Litigation Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. Payments cannot be issued until the court grants final approval and any appeals are resolved.
In the news
Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Tattooed Chef Securities Settlement
Tattooed Chef, Inc. faced a securities lawsuit alleging that purchasers of the company's common stock were damaged. The defendant has agreed to settle all claims in the action for $4,750,000 in cash without admitting wrongdoing.
Estée Lauder Securities Settlement
Estée Lauder is settling securities litigation relating to alleged damages to investors who purchased or acquired publicly traded common stock of The Estée Lauder Companies Inc. during the class period. The defendant has not admitted wrongdoing in this settlement.
E-Commerce China Dangdang Securities Settlement
E-Commerce China Dangdang, Inc. was involved in a take-private transaction (merger) that closed on September 20, 2016. Shareholders who held American Depositary Shares during the Class Period claim they were harmed by undisclosed information related to the Company's take-private transaction. The defendant has agreed to settle these securities claims without admitting wrongdoing.
Evolv Technologies Holdings Securities Settlement
Investors purchased publicly traded common stock of Evolv Technologies Holdings Inc. during a specific period and are entitled to compensation from a securities class action settlement. The page does not explicitly state what wrongdoing Evolv allegedly committed.